All In Biotech

Drug Trial Radar · NCT02718716

Study to Evaluate Safety, Tolerability and Efficacy of UCB7665 in Subjects With Primary Immune Thrombocytopenia

A Multicenter, Open-label, Multiple-dose Study to Evaluate the Safety, Tolerability, and Efficacy of UCB7665 in Subjects With Primary Immune Thrombocytopenia

Last checked: Nov 20, 2026Latest source record: Jan 29, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

66

Actual

Start

Mar 2, 2016

Primary completion

Feb 4, 2019

Study completion Feb 4, 2019

Sponsor

Lead sponsor
UCB Biopharma SRLUCB
Sponsor type
Industry
Collaborators
Parexel
First posted
Mar 24, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of the study is to check if an subcutaneous (sc) infusion of UCB7665 is safe and tolerated in subjects with primary immune thrombocytopenia.

Conditions

  • Thrombocytopenia

Interventions

  • UCB7665Drug

    * Intervention Type: Biological/Vaccine * Pharmaceutical Form: Powder for solution for infusion * Concentration: 100 mg/ml - Route of Administration: Subcutaneous infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants Experiencing at Least One Treatment Emergent Adverse Event (TEAE) During the StudyTime frame: From Visit 2 (Week 1) until End of Study Visit or Early Termination (up to 12 weeks after the first investigational medicinal product (IMP) administration)

Locations

29 sites in 11 countries. Site status is shown where the registry gives one.

  • Tp0001 1101

    Adelaide, Australia

  • Tp0001 1302

    Pleven, Bulgaria

  • Tp0001 1301

    Sofia, Bulgaria

  • Tp0001 203

    Olomouc, Czechia

  • Tp0001 201

    Prague, Czechia

  • Tp0001 1201

    Tbilisi, Georgia

  • Tp0001 401

    Berlin, Germany

  • Tp0001 403

    Düsseldorf, Germany

  • Tp0001 404

    München, Germany

  • Tp0001 502

    Florence, Italy

  • Tp0001 506

    Torino, Italy

  • Tp0001 503

    Udine, Italy

  • Tp0001 505

    Vicenza, Italy

  • Tp0001 601

    Chisinau, Moldova

  • Tp0001 702

    Bialystok, Poland

  • Tp0001 703

    Gdansk, Poland

  • Tp0001 701

    Lodz, Poland

  • Tp0001 704

    Poznan, Poland

  • Tp0001 705

    Warsaw, Poland

  • Tp0001 802

    Brasov, Romania

  • Tp0001 801

    Bucharest, Romania

  • Tp0001 803

    Craiova, Romania

  • Tp0001 902

    Madrid, Spain

  • Tp0001 903

    Madrid, Spain

  • Tp0001 901

    Valencia, Spain

  • Tp0001 1001

    London, United Kingdom

  • Tp0001 1002

    London, United Kingdom

  • Tp0001 1003

    London, United Kingdom

  • Tp0001 1004

    Truro, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.